Paul Rickey
2021
In 2021, Paul Rickey earned a total compensation of $1.7M as Senior Vice President and Chief Financial Officer at Nivalis Therapeutics, a 117% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $186,000 |
|---|---|
| Option Awards | $1,076,618 |
| Salary | $400,000 |
| Total | $1,662,618 |
Rickey received $1.1M in option awards, accounting for 65% of the total pay in 2021.
Rickey also received $186K in non-equity incentive plan and $400K in salary.
Rankings
In 2021, Paul Rickey's compensation ranked 6,804th out of 12,415 executives tracked by ExecPay. In other words, Rickey earned more than 45.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,804 out of 12,415 | 45th |
Division Manufacturing | 2,957 out of 5,505 | 46th |
Major group Chemicals And Allied Products | 1,308 out of 2,375 | 45th |
Industry group Drugs | 1,166 out of 2,096 | 44th |
Industry Pharmaceutical Preparations | 851 out of 1,546 | 45th |
Source: SEC filing on April 29, 2022.
Rickey's colleagues
We found three more compensation records of executives who worked with Paul Rickey at Nivalis Therapeutics in 2021.